Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. came to market through a business combination with Health Sciences Acquisitions Corporation 2 (Nasdaq: HSAQ), a blank-check company sponsored by Health Sciences Management Partners that completed its IPO in 2021 targeting the healthcare and life sciences sector. The October 2023 S-1 filing, bearing accession number 0001104659-23-108348, reflects the company's post-combination registration as a publicly traded medical device and biomedical technology firm focused on cardiovascular and hypertension therapies. Orchestra BioMed's lead programs include cardiac neuromodulation and drug-coated balloon technologies aimed at addressing large unmet needs in cardiovascular care. The de-SPAC transaction brought the operating company onto Nasdaq under its current public structure. For complete filing history, sponsor details, and deal analytics on HSAQ and thousands of other SPACs, sign up for full data access at SpacDesk.